Connect with us

Cannabis News

State-Licensed Marijuana Businesses Can Now Apply For Federal Protections Using New DEA Form

Published

2 months ago

on

State licensee Medical marijuana companies can apply for federal protections In line with the Trump administration’s cannabis reprogramming process.

The Drug Enforcement Administration’s “Medical Marijuana Dispensary Registry Portal” went live Wednesday morning.

The move comes after the Justice Department announced that last week Marijuana Schedule I through III of the Controlled Substances Act (CSA), in stages.

Pursuant to an order signed by Attorney General Blanche, marijuana products regulated by a state medical cannabis license were immediately moved to Title III.

III. State-licensed medical cannabis dispensaries that wish to take advantage of the new legal protections and tax benefits that come with annexation status must first file an application with the DEA requesting information about their processes for storage, ordering, distribution, inventory, record keeping and other aspects of their business.

For each activity below, indicate whether the company has a standard operating procedure (SOP):

    • the order
    • receiving
    • Inventories
    • Marijuana storage
    • security
    • Distribution (including delivery services)
    • to divide
    • Destruction/Disposal
    • Reporting Theft/Loss
    • Due diligence (including provider/patient/professional verification)
    • Corresponding Liability
    • Record keeping”

The application asks about specific details of security measures such as vaults, safes, secure storage, access controls, alarm systems and on-site security personnel.

Applicants can choose whether to apply for administration of marijuana, marijuana extracts, or naturally derived delta-9 THC.

Currently, with only medical marijuana moving to Schedule III, the application asks potential registrants whether their businesses handle or provide recreational marijuana.

According to last week’s DOJ order, an expedited administrative hearing process will be held beginning June 29 to consider the broader cannabis reorganization.

The DEA application, meanwhile, also asks companies to submit information about their state’s cannabis licenses and to answer questions about their criminal and disciplinary history.

It also asks, “Has anyone involved in the ownership or operation of the business previously manufactured, distributed, and/or provided a controlled substance without a DEA registration authorizing such activity?”

Allegedly every illegal cannabis company operating in the state today has key employees who have done so, medical marijuana was a Schedule I substance whose manufacture, distribution and general distribution was not permitted by the DEA until just a few days ago.

Applicants must also list the suppliers from whom they plan to procure marijuana, and report whether they plan to repackage or relabel cannabis products.

They must also provide lists of people whose business they expect to have “access to controlled substances,” including their dates of birth, social security numbers, and drug-related criminal histories.

“Provide the following for each person you plan to acquire controlled substances:

    • The name
    • Title(s)
    • date of birth
    • Social Security number
    • DEA registration numbers, if applicable
    • State/territory permits to manufacture, distribute, dispense, or otherwise handle controlled substances
    • Has this person been subject to one or more federal, state, territorial, or tribal disciplinary actions?
    • Has this person been convicted of federal, state, territorial, tribal, or local offenses related to controlled substances?

There is also $794 per year the application fee, currently only payable through PayPal, although DEA ​​”expects to have additional payment methods in the coming weeks.”

Application fees are non-refundable.

Separately, the DEA has launched a new web page on its website that contains key information about the new federal rescheduling move for cannabis, including copies of Federal Register orders outlining the process for the amendment and the upcoming litigation.

Blanche’s reorganization order last week said that to comply with the international drug control treaty’s “requirement that a government agency act as the exclusive purchaser of cannabis production,” the DOJ is setting in motion a process by which the federal government technically buys from marijuana producers and then sells to them or related entities.

“Registered growers must store the crops in a DEA-accessible facility until that transaction is completed, and each grower’s registration must specify the area in which the grow is allowed,” he said.

“All manufacturers registered under this subsection shall establish a nominal price for the purchase of their marijuana crops. The Administration shall then purchase the entity’s crops at that price and resell the crops to the entity, or a related or supporting entity, at the same price plus the administrative fee calculated in section 1318.06(a)..”

Meanwhile, the US Treasury and Internal Revenue Service (IRS) said they plan to issued new tax guidelines for the marijuana industry after the reorganization announcement.

The reorganization will benefit state-licensed marijuana businesses by allowing them to take federal tax deductions that are currently prohibited under IRS Code Section III, known as Section 280E.

White House Press Secretary Karoline Leavitt said the administration is moving forward with the marijuana overhaul because Cannabis reform is “very popular” with voters and because doing so will help people who need access to the drug for medical purposes.

At the press event held in the Oval Office last week, President Donald Trump spoke about the medical benefits of marijuana.

“A lot of people are facing big problems, and that seems to be the best answer,” he said. “They’re very happy. So the reorganization begins, and that’s a big thing, the reprogramming.”

The president stated that his administration’s rescheduling of cannabis came about after his friend Howard Kessler told him about his use of medical marijuana.

“He had some medical difficulties, and it came about by chance, kind of,” he said. “He had to go through a lot of different medications, and he said this was the one that was so much better than anything else. And so he lived through that. He didn’t benefit from it, because now he lives much better from the perspective.”

“So we hope you don’t have to,” Trump said. “But if you must, I hear it’s the best of all alternatives.”

Separately, the president asked Congress to take action changing the law that threatens to federally recriminalize hemp-derived full-spectrum CBD products later this year

“We need to do this STRAIGHT and FAST, especially for those who have found CBD helping them,” he said in a social media post. “Also, I’m told it will help our BIG FARMERS that we love and will always be around.”

A few days ago, Trump denounced this Federal officials were “slowly” pursuing his cannabis warrant.

Marijuana Moment is made possible with the help of readers. If you rely on our pro-cannabis journalism to stay informed, consider a monthly Patreon pledge.

Related Topics:
Continue Reading

Cannabis News

Massachusetts CCC pauses license applications

Published

6 hours ago

on

June 17, 2026

By











The Cannabis Control Commission, the government body that oversees the marijuana business in the state of Massachusetts (USA), has decided to temporarily stop accepting new license applications for growing marijuana, both indoors and outdoors. This hiatus officially began on June 16, 2026.

Anyone planning to apply for a new marijuana cultivation license after June 16, 2026 will not be able to do so while this suspension is in effect. The Commission will not accept such requests during this period.

There are two groups that can continue normally. First, anyone who submitted an application before June 16, 2026, will continue to review and process applications as usual. Second, applicants for specific programs designed to help communities historically affected by drug laws, known as the Social Equity Program and the Economic Empowerment Program, are exempt from this suspension if they apply for a smaller-scale “Microenterprise” license.

The suspension will be in effect for 120 days from June 16, 2026, which is currently scheduled to be lifted around mid-October 2026. However, the Commission has the power to terminate earlier or extend further, depending on market conditions.

Source: Massachusetts Cannabis Control Commission










Continue Reading

Cannabis News

Federal Marijuana Rescheduling ‘Does Not Appear To Apply’ To Washington Businesses, State Officials Say

Published

6 hours ago

on

June 17, 2026

By

Marijuana regulators in Washington say the Trump administration’s move to re-regulate cannabis at the federal level “doesn’t appear to apply” to the state’s businesses.

US Department of Justice in April He issued an order that immediately reclassified the state’s licensed medical cannabisas well as marijuana products approved by the Food and Drug Administration (FDA) under Schedule I through Schedule III of the Controlled Substances Act (CSA). A trial scheduled for this month will take place consider marijuana III.

“Washington does not issue licenses to producers, processors or retailers of medical cannabis,” the state’s Liquor and Cannabis Board (LCB) said in guidelines released Tuesday. “Instead, Washington has a single recreational market and within that market producers/processors can manufacture (DOH) compliant products, and certain retailers can sell DOH-compliant products to adult patients and all designated providers.”

“Therefore, Washington cannabis licensees do not appear to qualify as ‘state medical marijuana licensees’ and therefore may not be eligible for registration under the final Rule,” the agency said, referring to the Drug Enforcement Administration (DEA). Registration process for legal marijuana businesses in the state to take advantage of the federal benefits that come with the reform.

That said, the LCB “does not take a position if licensees decide to apply for federal registration,” the guidance continues. “If a licensee is seeking federal registration, we would be interested in learning about their experience and federal decisions.”

However, “based on our analysis, the federal reorganization in its current form does not appear to apply to cannabis licensees in Washington, primarily because of the legal framework governing recreational cannabis,” the LCB said.

The agency emphasized, however, that while it has consulted with the Cannabis Regulatory Association, the National Governors Association and industry stakeholders, its current opinion does not represent Washington’s formal opinion and “may not be our final interpretation as information is evolving and the decision may not rest with the state.”

“We await additional guidance from the federal agencies involved, new or updated federal agency processes and/or other federal procedures,” he said. he saidreferring to the next administrative hearing and Ongoing litigation calls into question the rescheduling of cannabis.

“The LCB recognizes that there are many cannabis growers, processors, and retailers actively involved in the production and sale of medical cannabis in Washington. These businesses may or may not be eligible to use the 280e tax deduction, and may also register with the DEA III. Ultimately, they have no input into whether their licensees meet the criteria for “state medical marijuana licensees,” as that determination can be made unilaterally by the DOJ within the meaning of the Final Rule. to reasonably interpret and determine that Washington cannabis licensees qualify as “state medical marijuana licensees.”

The US Treasury and Internal Revenue Service (IRS) said they plan to issued new tax guidelines for the marijuana industry after reprogramming. The reform will benefit state-licensed marijuana businesses by allowing them to take federal tax deductions that are currently prohibited under IRS Code Section III, known as Section 280E.

In California, regulators recently approved emergency rule changes to the state’s marijuana licensing process. to make it easier for companies to receive benefits In line with the Trump administration’s latest move to federally regulate medical cannabis.

Marijuana Moment is made possible with the help of readers. If you rely on our pro-cannabis journalism to stay informed, consider a monthly Patreon pledge.

Continue Reading

Cannabis News

How New Zealand showed up in London’s cannabis industry

Published

1 day ago

on

June 16, 2026

By

The medical cannabis market is expected to grow from $47 billion to $149 billion by 2031, and New Zealand has a real role to play in that story. And thanks in large part to New Zealand Trade and Enterprise (NZTE), the government’s international business development agency, Puro is starting to play.

At Cannabis Europa 2026 London, NZTE hosted an evening event at the City Arts Bar with Puro, New Zealand companies Bluelab, Rua Bioscience and CannFX. Puro called it The NZ Room.

Beyond all things Kiwiana – including Puro brand kiwifruit, Kiwi’d – the room was filled with some pretty amazing people: Ivy League scientists, company founders, patients, advocates, industry players, government officials, Maori tribal leaders and a tough Scotsman. All in the same space with the same true passion for where this industry is going.

It was one of those rooms where conversations went well when they had to end. That’s usually a sign of something well done.

Made possible by NZTE
For Puro, the NZTE relationship has been formative. With ongoing support, Puro has entered the Australian market with 47 unique product SKUs and signed a £7 million supply agreement with UK distributor IPS Pharma.

NZTE understands the potential of the New Zealand cannabis industry. The willingness to support this nascent industry and put New Zealand in the spotlight at events like Cannabis Europa is very significant. New Zealand is a small country and the country’s credibility in international markets is built from relationship to relationship, room by room. NZTE helps build those rooms.

© Cigar

what’s next
For the first time, patients in the UK have access to medicinal cannabis grown in New Zealand. That’s the direct result of years of work by Puro’s team, but it’s not worth much if you can’t connect with buyers globally. Creating international relationships that events like Cannabis Europa make this possible.

“We are grateful for the extensive support from the New Zealand Government that drives our progress, including the Ministry of Primary Industries’ support for our genetic breeding, product innovation and market access goals. This collective effort from agencies such as the Ministry of Business, Innovation and Employment, NZTE and the New Zealand Export Credit Bureau ensures that Mail that started in London will continue to grow in Puro’s international goals,” he said. a statement

For more information:
clean
www.puro.co.nz

Continue Reading
Advertisement

Trending

Copyright © 2021 The Art of MaryJane Media